Navigation Links
Epizyme, Inc. Reports Second Quarter 2013 Financial Results
Date:7/31/2013

Net loss was $2.2 million for the second quarter of 2013 and $9.7 million for the six months ended June 30, 2013, compared to net income of $4.9 million and net loss of $0.6 million for the comparable periods in 2012. The 2012 second quarter net income was largely driven by the revenue recognition of a portion of the $68.0 million upfront payment received from Celgene in April 2012.
  • End of Year Cash Guidance Epizyme expects that its cash and cash equivalents will be approximately $115 million as of December 31, 2013, which it believes will fund the Company until at least mid-2015. Full-year 2013 net cash used in operating activities is expected to be approximately $65 million.
  • Upcoming Milestones

  • EPZ-5676 In the second half of 2013, Epizyme plans to complete the dose escalation stage of the Phase 1 study and initiate the expansion cohort, which will be limited to patients with MLL-r and which may provide an initial assessment of therapeutic effect.
  • EPZ-6438 In 2014, Epizyme plans to initiate the Phase 2 portion of the Phase 1/2 study of EPZ-6438, which will be limited to patients with point mutations in EZH2 and which may provide an initial assessment of therapeutic effect.
  • Conference Call InformationEpizyme will host a conference call and live audio webcast today at 4:30 p.m. EDT to discuss the quarter and provide a corporate update. To participate in the conference call, please dial 1-877-844-6886 (domestic) or 1-970-315-0315 (international) and refer to conference ID 17477005. The live webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com

    The archived webcast will be available on the Company's website beginning approximately two hours after the event.

    About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients w
    '/>"/>

    SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. China Medical Flat Panel Detector Market & Pressure Injector 2013 Research Reports Now Available at ReportsnReports.com
    2. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
    3. Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope
    4. China Radiotherapy Simulator Market & Digital Radiography 2013 Research Reports Now Available at ReportsnReports.com
    5. Neurocrine Biosciences Reports Second Quarter 2013 Results
    6. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
    7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
    8. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
    9. Cepheid Reports 2013 Second Quarter Results
    10. Quest Diagnostics Reports Second Quarter 2013 Financial Results
    11. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... UAE (PRWEB) October 30, 2014 Grace Century ... Dr. James A. Manganello, Chairman of the Board, to the ... Bahamas. The appointment was made by the Ministry of ... September 24th, 2014. , More than a year ... Research Bill , Prime Minister Perry Christie said the government ...
    (Date:10/30/2014)... Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... a conference call and live audio webcast on Thursday, ... its third quarter 2014 financial results. Interested ... dialing (888) 347-1165 for domestic callers or (412) 902-4276 ... live under the investor relations section of the Regado ...
    (Date:10/27/2014)... Ryan Carfley , Managing Partner at Personify ... Bryan Hamilton, the publisher of the Triangle Business Journal, and ... Research Triangle region of North Carolina. , Just a few ... include the role of social media in recruitment, recruiting ... the unique role that Millennials play in the workplace today. ...
    (Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... today announced two presentations demonstrating that the extent ... proprietary cancer immunotherapeutic AE37 vaccine correlated with a ... AE37 cancer vaccine is being developed by the ... ). The presentations are being made at the ...
    Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
    ... Oncology Adjuvant Trial 9735 at 2007 San, ... Improved Overall Survival Versus ... Results presented at the,30th annual San Antonio ... early stage breast cancer who have had surgery, ...
    ... FDA-defined Valvulopathy Permitted to Enroll in 2nd and ... Screening Requirement Eliminated, SAN DIEGO, Dec. 13 ... announced the initiation of patient screening in,the second ... efficacy and,safety of its lead drug candidate, lorcaserin ...
    ... SAN DIEGO, Dec. 13 BioMed Realty Trust, Inc.,(NYSE: ... I. Gilchrist to its,board of directors, increasing the board ... in the real estate industry, with a breadth of,ability ... large-scale commercial real estate projects. We believe that,Rick,s contributions ...
    Cached Biology Technology:Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 2Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 3Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 4Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 6BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3
    (Date:10/29/2014)... study of its kind to date, researchers have used ... the risk for autism. Joseph Buxbaum, Ph.D., Icahn School ... Daly, Ph.D., Broad Institute of Harvard and MIT, and ... affected children, parents and unrelated people. They identified changes ... the risk for autism spectrum disorder (ASD) – a ...
    (Date:10/29/2014)... factors, both genetic and environmental, have been blamed ... schizophrenia. Some, such as a family history of ... with Toxoplasma gondii , a parasite transmitted ... still viewed with skepticism. , A new study ... epidemiology at the University of Pennsylvania,s School of ...
    (Date:10/29/2014)... nanoparticles is all the rage. Thousands of scientists worldwide ... of whether titanium dioxide nanoparticles from sun creams can ... carbon nanotubes from electronic products are as hazardous for ... nanoparticles in food can get into the blood via ... research funds are flowing – and the number of ...
    Breaking Biology News(10 mins):Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
    ... 02 April 2011: Thalidomide has shown potential to be used ... to data presented at the International Liver CongressTM 2011.1 ... grossly curative resection surgical removal of the cancerous ... free survival rate (65%) compared to placebo (33%). However, ...
    ... SPAINIrrigating agricultural crops places huge demands on water ... where agriculture is a major contributor to the ... comes from the agricultural sector. The excessive use ... concerns in Mediterranean countries, where rising demand has ...
    ... Ore. Engineers at Oregon State University have ... in the production of low-temperature, microchannel heat exchangers ... technology much less expensive for many commercial applications. ... researchers say, in next-generation computers, lasers, consumer electronics, ...
    Cached Biology News:Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients 2Research on satellite imagery aims to advance sustainable agriculture 2Advance in microchannel manufacturing opens new industry applications 2
    Anti-Human alpha2-Antiplasmin Purified (Polyclonal) (goat IgG)...
    Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
    ... The Mini-PROTEAN 3 Dodeca cell with multi-casting chamber ... up to 12 mini format handcast (8.3 x ... gels. The cell requires 3.4-4.4 L of buffer ... coil that attaches to an external refrigerated circulator ...
    ... thin foil heat sealing material is ... from a screw down heated lid), ... a useful method for sample retrieval. ... the existing seal. Ideal for compound ...
    Biology Products: